Latest News on AMPH

Financial News Based On Company


Advertisement
Advertisement

After exercising options at $17.99, the CFO of Amphastar (AMPH) sold 11,000 shares at $29.99 per share.

https://www.stocktitan.net/sec-filings/AMPH/form-4-amphastar-pharmaceuticals-inc-insider-trading-activity-827d1630b189.html
Amphastar Pharmaceuticals, Inc. (AMPH) CFO, EVP & Treasurer William J. Peters exercised 11,000 options at $17.99 per share on November 16, 2026, and subsequently sold 11,000 common shares at $29.99 per share on the same day. This transaction was conducted under a Rule 10b5-1 trading plan adopted in March 2026. Following the exercise, Peters holds 56,833 employee stock options and 167,076 common shares.

Form 144 Amphastar Pharmaceuticals For: 17 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-amphastar-pharmaceuticals-for-17-november-93CH-4962961
This article from Investing.com announces the filing of Form 144 for Amphastar Pharmaceuticals (AMPH) on November 17, 2026. Form 144 is a notice of the intent to sell restricted securities, typically filed by company insiders. The article provides no further details beyond this announcement.

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London

https://www.prnewswire.com/news-releases/amphastar-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-in-london-302935832.html
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference in London. The event is scheduled for Wednesday, November 18, 2026, at 12:00 pm GMT. A webcast of the presentation will be available for 30 days on the company's investor relations website.

Under a trading plan, Amphastar (AMPH) CFO Peters sells 12,631 shares at about $28.99 each.

https://www.stocktitan.net/sec-filings/AMPH/form-4-amphastar-pharmaceuticals-inc-insider-trading-activity-8ac8a0af4e1b.html
Amphastar Pharmaceuticals, Inc. CFO William J. Peters sold a total of 28,631 shares across two days in November 2026 under a Rule 10b5-1 trading plan. He sold 16,000 shares at $28.03 each on November 4 and an additional 12,631 shares at a weighted average price of $28.9913 on November 5. These sales followed the exercise of employee stock options.

Amphastar Pharmaceuticals stock hits 52-week high at $30.34 By Investing.com

https://in.investing.com/news/stock-market-news/amphastar-pharmaceuticals-stock-hits-52week-high-at-3034-93CH-5687637
Amphastar Pharmaceuticals Inc. (AMPH) stock recently hit a 52-week high of $30.34 and is currently trading at $29.72 with a market capitalization of $1.18 billion. InvestingPro analysis suggests the stock is undervalued with a Fair Value of $35.23, highlighting its strong performance with a 15.11% gain over the past year. The company reported record third-quarter 2026 revenue of $207.6 million, surpassing Wall Street expectations, driven by strong sales of branded products despite increased FDA-related remediation costs.
Advertisement

Amphastar Pharmaceuticals stock hits 52-week high at $30.34 By Investing.com

https://ca.investing.com/news/stock-market-news/amphastar-pharmaceuticals-stock-hits-52week-high-at-3034-93CH-4939631
Amphastar Pharmaceuticals stock reached a new 52-week high of $30.34 and is currently trading at $29.72, with InvestingPro analysis suggesting it is undervalued at a Fair Value of $35.23. The company also reported record third-quarter 2026 revenue of $207.6 million, exceeding Wall Street expectations, driven by strong sales of branded products like BAQSIMI and Primatene MIST. Despite increased FDA-related remediation costs, the company's board authorized an additional $50 million for share repurchases.

Quarterly profit rose to $37.8 million at Amphastar, from $17.4 million a year ago.

https://www.stocktitan.net/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-0i3xl2j8svdg.html
Amphastar Pharmaceuticals reported third-quarter 2026 revenue of $207.6 million, an 8% increase year over year, with GAAP net income rising to $37.8 million from $17.4 million a year ago. The company's board also authorized a $50 million increase to its share buyback program to offset equity-compensation dilution. While sales of BAQSIMI and Primatene MIST increased, gross margin declined due to pricing pressure and higher manufacturing expenses.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

https://www.tradingview.com/news/prnewswire:79b6b5df4c76f:0-amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-september-30-2026/
Amphastar Pharmaceuticals, Inc. reported net revenues of $207.6 million for the third quarter ended September 30, 2026, an 8% increase year-over-year, driven by record sales of BAQSIMI® and Primatene MIST®. The company achieved GAAP net income of $37.8 million, or $0.87 per share, and adjusted non-GAAP net income of $49.3 million, or $1.14 per share. Additionally, Amphastar's Board of Directors authorized a $50 million increase to its share buyback program.

Amphastar Pharmaceuticals, Inc. (AMPH) Adds $50M to Buyback Program

https://www.tradingview.com/news/tradingview:70496708f4ccb:0-amphastar-pharmaceuticals-inc-amph-adds-50m-to-buyback-program/
Amphastar Pharmaceuticals, Inc. (AMPH) announced that its board of directors authorized a $50 million increase to its share buyback program on November 4, 2026. This decision accompanies the company's Q3 2026 results and a reported $142.5 million in operating cash flow for the first nine months of the year, although prior-period comparisons for cash flow were not provided in the release. The expanded repurchase capacity is primarily intended to offset dilution from equity compensation.

Amphastar Pharmaceuticals, Inc. $AMPH Stock: Bridge City Capital LLC Boosts Position

https://www.marketbeat.com/instant-alerts/filing-amphastar-pharmaceuticals-inc-amph-stock-bridge-city-capital-llc-boosts-position-2026-11-02/
Bridge City Capital LLC increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 13.3% in the third quarter, bringing its total holdings to 383,901 shares valued at $9.9 million. This makes Amphastar Pharmaceuticals its sixth-largest position, representing 2.1% of its investment portfolio. Despite the company reporting stronger-than-expected quarterly earnings and revenue, analyst sentiment remains cautious with an average "Reduce" rating and a price target of $22.50, below its current trading price of $27.72.
Advertisement

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026

http://www.streetinsider.com/PRNewswire/Amphastar+Pharmaceuticals+to+Release+Third+Quarter+Earnings+and+Hold+Conference+Call+on+November+5%2C+2026/27251498.html
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026. The company will also host a conference call at 2:00 p.m. Pacific Time to discuss these results. Details for accessing the call and webcast replay are provided.

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026

https://www.tradingview.com/news/prnewswire:1b4d640d9da62:0-amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-november-5-2026/
Amphastar Pharmaceuticals, Inc. (AMPH) announced it will release its third-quarter 2026 earnings after market close on Thursday, November 5, 2026. The company will also hold a conference call to discuss these financial results at 2:00 p.m. Pacific Time on the same day. Investors can access the call via phone or webcast on the company's website.

Amphastar Pharmaceuticals, Inc. Estimates – NASDAQ:AMPH

https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-estimates/
This article provides access to the financial estimates for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) on TradingView. It allows users to explore reported financial data and analyst estimates, comparing actual results with average, high, and low estimates across various financial statements. The platform aims to visualize trends over time for informed decision-making.

Amphastar Pharmaceuticals, Inc. (AMPH) Stock forecasts

https://au.finance.yahoo.com/research/reports/ARGUS_4735_QuantitativeReport_1791936000000
This report from Argus provides a quantitative analysis of Amphastar Pharmaceuticals Inc. (AMPH). It includes a current price of $26.14 and offers a summary of the company as a biopharmaceutical firm specializing in generic and proprietary injectable, inhalation, and intranasal products, as well as insulin APIs. The full report can be downloaded for more detailed insights.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Crosses Above 50 Day Moving Average - Should You Sell?

https://www.marketbeat.com/instant-alerts/price-amphastar-pharmaceuticals-nasdaq-amph-share-price-crosses-above-50-day-moving-average-should-you-sell-2026-10-13/
Amphastar Pharmaceuticals (AMPH) recently saw its share price rise above its 50-day moving average, reaching $26.86 compared to the average of $23.27. Despite beating quarterly earnings and revenue estimates, analyst sentiment remains cautious with a "Reduce" rating and a consensus price target of $22.50, partly due to significant insider stock sales. Institutional investors have been increasing their positions in the company.
Advertisement

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4735_QuantitativeReport_1791331200000
Argus has lowered its target price for Amphastar Pharmaceuticals Inc. (AMPH) to $27.00. The biopharmaceutical company, which specializes in generic and proprietary injectable, inhalation, and intranasal products, currently trades at $26.62. Investors can upgrade to premium research reports for detailed insights.

Amphastar Pharmaceuticals Inc Share Price - AMPH, RNS News, Articles, Quotes, & Charts

https://www.proactiveinvestors.com/companies/16597/Amphastar-Pharmaceuticals-Inc
This article provides an overview of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH), a specialty pharmaceutical company focused on injectable and inhalation products. It includes current market data, recent news such as FDA approvals and a drug sale to Eli Lilly, and general company information, highlighting its market capitalization, 52-week high and low, and product development strategy.

Amphastar Pharmaceuticals (NasdaqGS:AMPH) Stock Price

https://simplywall.st/stock/nasdaqgs/amph
Amphastar Pharmaceuticals (NasdaqGS:AMPH) has a current share price of US$26.62, which is 13.23% higher than its fair value of US$22.50, indicating it is 18.3% overvalued. Analyst narratives highlight concerns about pricing pressure and a concentrated generics mix threatening long-term earnings, while others suggest pipeline expansion and U.S. capacity could drive upside. The company's financials show US$730.0m in revenue and US$78.5m in earnings, with a gross margin of 47.68%.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Raised to Strong-Buy at Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-amphastar-pharmaceuticals-nasdaq-amph-stock-rating-raised-to-strong-buy-at-wall-street-zen-2026-10-03/
Wall Street Zen has upgraded Amphastar Pharmaceuticals (NASDAQ:AMPH) to a "strong-buy" rating, despite a broader analyst consensus of "Reduce" with an average price target of $22.50. The company recently surpassed quarterly expectations, reporting $0.91 EPS against a $0.62 consensus and revenues of $183.9 million, exceeding estimates of $179.92 million. Insider selling activity totaling 33,479 shares worth approximately $763,922 has been noted over the past 90 days.

AMPH5896384 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-AMPH5896384/profile/
This article provides a detailed bond profile for AMPH5896384 issued by Amphastar Pharmaceuticals, Inc., featuring a 2.0% coupon rate and maturing on March 15, 2029. It outlines key facts such as issue and maturity dates, face value, and minimum denomination, along with an upcoming semi-annual coupon payment schedule. The profile also touches on the company's business and bond redemption details, including an outstanding amount of $345.00 million USD.
Advertisement

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of "Reduce" from Analysts

https://www.marketbeat.com/instant-alerts/consensus-amphastar-pharmaceuticals-inc-nasdaq-amph-receives-average-rating-of-reduce-from-analysts-2026-09-30/
Eight analysts currently covering Amphastar Pharmaceuticals (NASDAQ:AMPH) have issued a consensus "Reduce" rating, with two recommending "sell" and six recommending "hold". Despite this, the company's shares opened at $26.68, above the average 12-month price target of $22.50, and recent quarterly results exceeded expectations with $0.91 EPS and $183.9 million in revenue. Over the past three months, insiders sold shares worth approximately $763,922, while institutional investors own 65.09% of the stock.

Bank of America Corp DE Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-investment-in-amphastar-pharmaceuticals-inc-amph-2026-09-30/
Bank of America Corp DE recently acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the second quarter, purchasing 136,824 shares valued at approximately $2.76 million. Despite this new investment, analysts maintain a cautious outlook on AMPH with a consensus "Reduce" rating and an average price target of $22.50. The company reported strong Q2 earnings, surpassing revenue and EPS estimates, yet insider selling activity has been noted.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Up 5.7% - What's Next?

https://www.marketbeat.com/instant-alerts/price-amphastar-pharmaceuticals-nasdaq-amph-shares-up-57-whats-next-2026-09-28/
Amphastar Pharmaceuticals (NASDAQ:AMPH) shares rose 5.7% despite low trading volume, following better-than-expected quarterly earnings with $0.91 EPS against a $0.62 consensus and revenue of $183.9 million. Despite the positive earnings, analysts maintain a "Reduce" rating and a $22.50 price target, and insiders have recently sold over $760,000 worth of shares, suggesting a cautious outlook. The company specializes in injectable, inhaled, and intranasal biopharmaceutical products, including those for diabetes and respiratory conditions.

Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO Sells 4,139 Shares

https://www.marketbeat.com/instant-alerts/insider-insider-selling-amphastar-pharmaceuticals-nasdaq-amph-cfo-sells-4139-shares-2026-09-23/
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters sold 4,139 shares of the company's stock for a total of $103,475 under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Peters still directly owns 168,707 shares valued at approximately $4.2 million. The company recently reported strong quarterly earnings, significantly beating analyst estimates, although the consensus analyst rating remains "Reduce" with an average price target below the current trading price.

At $25 a share, Amphastar Pharmaceuticals (AMPH) CFO William Peters sold 4,139 shares.

https://www.stocktitan.net/sec-filings/AMPH/form-4-amphastar-pharmaceuticals-inc-insider-trading-activity-094357540b66.html
Amphastar Pharmaceuticals' CFO, EVP & Treasurer William J. Peters, sold 4,139 shares of common stock at $25 per share on September 21, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted on March 10, 2026, leaving him with 168,707 shares directly held. The insider sale, totaling approximately $103,000, was reported in a Form 4 filing with the SEC.
Advertisement

Amphastar (NASDAQ: AMPH) exec plans 4,139-share Rule 144 sale

https://www.stocktitan.net/sec-filings/AMPH/144-amphastar-pharmaceuticals-inc-sec-filing-11d593f255ce.html
An officer at Amphastar Pharmaceuticals, Inc. (AMPH), William J. Peters, has filed a Rule 144 notice to sell 4,139 shares of common stock, valued at $103,475.00, with a proposed sale date of September 21, 2026. These shares were acquired via RSU vesting on March 17, 2024. The filing also indicates a previous sale of 8,180 shares on August 7, 2026, generating $183,886.40.

Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou Sells 10,000 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-amphastar-pharmaceuticals-nasdaq-amph-evp-rong-zhou-sells-10000-shares-of-stock-2026-09-17/
Amphastar Pharmaceuticals EVP Rong Zhou sold 10,000 shares of the company's stock for $239,400, reducing her direct holdings by 5.58% to 169,203 shares. Despite the sale, Amphastar reported strong quarterly earnings, beating EPS and revenue estimates. Analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $22.50.

Squarepoint Ops LLC Has $1.59 Million Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

https://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-has-159-million-stock-holdings-in-amphastar-pharmaceuticals-inc-amph-2026-09-16/
Squarepoint Ops LLC significantly increased its stake in Amphastar Pharmaceuticals, Inc. by 178% in the second quarter, now holding 78,795 shares valued at $1.59 million. Despite this increase in institutional investment, analysts maintain a cautious "Reduce" rating for AMPH with a consensus price target of $22.50. The company recently surpassed quarterly earnings and revenue expectations, but corporate insiders have sold shares totaling $421,047 during the last quarter.

The Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call

https://finance.yahoo.com/healthcare/articles/top-5-analyst-questions-amphastar-041300648.html
Amphastar Pharmaceuticals reported Q2 results that exceeded analyst expectations, driven by strong demand for products like BAQSIMI and Primatene MIST, and the successful launch of ipratropium bromide. The earnings call highlighted key concerns from analysts regarding R&D and SG&A spending, the FDA warning letter for the IMS facility, business development strategies, market share targets for new products, and anticipated margins for the insulin aspart biosimilar. Management addressed these questions, providing insights into future cost drivers, regulatory remediation, acquisition preferences, and product outlooks.

Legal & General Group Plc Makes New $1.58 Million Investment in Amphastar Pharmaceuticals, Inc. $AMPH

https://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-makes-new-158-million-investment-in-amphastar-pharmaceuticals-inc-amph-2026-09-07/
Legal & General Group Plc has made a new investment of $1.58 million in Amphastar Pharmaceuticals (NASDAQ:AMPH), acquiring 78,281 shares, which represents a 0.18% stake. This investment comes as Amphastar Pharmaceuticals reported strong quarterly earnings, beating analyst expectations for both EPS and revenue. Despite positive earnings, analyst sentiment remains cautious with a consensus "Reduce" rating and insider selling activity observed over the past three months.
Advertisement

Bank of New York Mellon Corp Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH

https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-makes-new-investment-in-amphastar-pharmaceuticals-inc-amph-2026-09-06/
Bank of New York Mellon Corp recently acquired a new stake of 232,343 shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), valued at approximately $4.7 million. This investment gives Bank of New York Mellon Corp a 0.53% ownership stake in the company. Despite this institutional interest and strong Q2 earnings that beat analyst estimates, analyst sentiment remains cautious with an average "Reduce" rating for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Recommendation of "Reduce" from Analysts

https://www.marketbeat.com/instant-alerts/consensus-amphastar-pharmaceuticals-inc-nasdaq-amph-receives-consensus-recommendation-of-reduce-from-analysts-2026-09-05/
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received a "Reduce" consensus rating from analysts, with an average 12-month price target of $22.50, which is below its current share price of $23.18. Despite this, the company reported strong quarterly results, exceeding earnings and revenue expectations. Recent insider selling and increased institutional investor positions indicate mixed sentiment around the stock.

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

https://www.prnewswire.com/news-releases/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-21st-annual-healthcare-conference-302865707.html
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 4:30 pm ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company specializing in developing, manufacturing, and commercializing complex generic and proprietary injectable, inhalation, and intranasal products.

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

https://www.stocktitan.net/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-21st-annual-7cnockjnck4v.html
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that CFO Bill Peters and EVP Tony Marrs will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 4:30 p.m. ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. The company is a biopharmaceutical firm specializing in generic and proprietary injectable, inhalation, and intranasal products, and also sells active pharmaceutical ingredients.

Bank of America Corp DE Acquires 46,149 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-acquires-46149-shares-of-amphastar-pharmaceuticals-inc-amph-2026-08-31/
Bank of America Corp DE increased its stake in Amphastar Pharmaceuticals by 36% in the first quarter, purchasing an additional 46,149 shares and bringing its total holdings to 174,323 shares. This increased institutional ownership in the company to 65.09%, despite some insider selling. Amphastar Pharmaceuticals also reported strong quarterly earnings, surpassing analyst expectations with $0.91 EPS against an estimated $0.62.
Advertisement

(AMPH) and the Role of Price-Sensitive Allocations

https://news.stocktradersdaily.com/news_release/89/AMPH_and_the_Role_of_Price-Sensitive_Allocations_083026020202_1788069722.html
This article provides an in-depth analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes an exceptional risk-reward short setup targeting 15.3% downside.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Passes Above 50-Day Moving Average - Should You Sell?

https://www.marketbeat.com/instant-alerts/price-amphastar-pharmaceuticals-nasdaq-amph-stock-price-passes-above-50-day-moving-average-should-you-sell-2026-08-28/
Amphastar Pharmaceuticals (NASDAQ:AMPH) stock recently surpassed its 50-day moving average, trading at $21.88 against a moving average of $20.16. Despite exceeding quarterly earnings and revenue expectations, analyst sentiment remains cautious with a consensus "Reduce" rating and a $22.50 target price, partly due to recent insider stock sales. Institutional investors have shown mixed activity, with some increasing and others initiating positions.

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

https://www.easternprogress.com/analysts-estimate-amphastar-pharmaceuticals-amph-to-report-a-decline-in-earnings-what-to-look-out/article_274d5a02-d8f3-5f03-8c4e-3a8de1c648e6.html
Amphastar Pharmaceuticals (AMPH) is projected to report a year-over-year decline in earnings for the quarter ended June 2026, despite an expected increase in revenues. Analysts have recently become more bearish on the company's earnings prospects, leading to a negative Earnings ESP and a Zacks Rank of #5, making an earnings beat difficult to predict. Investors are advised to consider other factors beyond just an earnings beat or miss, and Supernus Pharmaceuticals (SUPN) is highlighted as a stronger earnings-beat candidate within the same industry.

Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH

https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/
The article focuses on the enterprise value to EBITDA forward metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It appears to be a financial data page from TradingView, providing an overview of the company's financial performance.

Denali Advisors LLC Has $7.59 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH

https://www.marketbeat.com/instant-alerts/filing-denali-advisors-llc-has-759-million-position-in-amphastar-pharmaceuticals-inc-amph-2026-08-20/
Denali Advisors LLC significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 41.1% in Q2, bringing its total holdings to 375,965 shares valued at $7.59 million. Despite Amphastar exceeding Q2 earnings expectations with $0.91 EPS against a $0.62 consensus, analyst sentiment remains cautious, with a "Reduce" rating and a $22.50 price target. This comes amidst insider share sales and institutional investors collectively owning a majority of the company's stock.
Advertisement

Barclays Issues Positive Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price

https://www.marketbeat.com/instant-alerts/barclays-issues-positive-forecast-for-amphastar-pharmaceuticals-nasdaqamph-stock-price-2026-08-18/
Barclays has increased its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) from $20 to $23, maintaining an "equal weight" rating and suggesting a 7.1% upside. Despite this, analyst sentiment remains cautious with a MarketBeat consensus rating of "Reduce" and an average target of $22.50. The company recently surpassed quarterly expectations, reporting $0.91 EPS against a $0.62 estimate and revenue of $183.9 million, exceeding the $179.9 million forecast.

Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise

https://www.stocktitan.net/sec-filings/AMPH/144-amphastar-pharmaceuticals-inc-sec-filing-be987293c214.html
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) insider Floyd Petersen plans to sell 47,101 shares of common stock, valued at $989,121, through UBS Financial Services Inc. This sale is being executed under Rule 144, following an option exercise for cash on August 18, 2026, which is also the proposed sale date. The transaction represents a small fraction of the 44,092,000 shares outstanding.

Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating

https://www.marketscreener.com/news/barclays-adjusts-price-target-on-amphastar-pharmaceuticals-to-23-from-20-maintains-equalweight-ra-ce7859dddb8cf720
Barclays has increased its price target for Amphastar Pharmaceuticals (AMPH) to $23 from $20, while maintaining an Equalweight rating on the stock. This adjustment comes after the company recently reported its Q2 2026 earnings, posting an adjusted EPS of $0.91, significantly exceeding the FactSet estimate of $0.62. Amphastar also reported Q2 revenue of $183.9M, surpassing the FactSet estimate of $179.9M.

Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/lead-independent-director-richard-prins-sold-a-bunch-of-shar
Amphastar Pharmaceuticals' Lead Independent Director, Richard Prins, recently sold US$162k worth of shares at an average price of US$20.30, reducing his holding by 27%. This was the largest insider sale in the past year for the company. While the sale occurred near the current stock price, which is not ideal, insiders still own 10% of Amphastar Pharmaceuticals, valued at about US$88 million.

Amphastar Pharmaceuticals (AMPH) Director Richard Prins Sells 7,973 Shares

https://www.gurufocus.com/news/9031205/amphastar-pharmaceuticals-amph-director-richard-prins-sells-7973-shares
Richard Prins, a director at Amphastar Pharmaceuticals (AMPH), sold 7,973 shares of the company for approximately $161,852 on August 11, 2026. This sale contributes to a trend of insider selling at AMPH over the past year, with no insider buys recorded. Despite the insider selling, GuruFocus pegs the stock as "Significantly Undervalued" with a price-to-GF-Value ratio of 0.57.
Advertisement

Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A

https://www.tradingview.com/symbols/MUN-29A/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/
This article focuses on the enterprise value to EBITDA forward for Amphastar Pharmaceuticals, Inc. (MUN:29A) as listed on the Munich Stock Exchange. It indicates that the market is currently closed with no trades. The information is presented within the financial section of a trading platform.

Amphastar director Richard Prins disposes of shares valued at $161,851

https://m.investing.com/news/insider-trading-news/amphastar-director-richard-prins-disposes-of-shares-valued-at-161851-93CH-4856416?ampMode=1
Amphastar Pharmaceuticals director Richard K. Prins sold 7,973 shares of the company's common stock for $161,851. This transaction occurred on August 11, 2026, with shares priced at $20.3 each, leaving him with 29,625 shares. The sale follows the company's strong Q2 2026 revenue of $183.9 million, surpassing analyst estimates, driven by new product success despite a 25% year-to-date stock decline.

Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

https://www.marketbeat.com/instant-alerts/richard-prins-sells-7973-shares-of-amphastar-pharmaceuticals-nasdaqamph-stock-2026-08-12/
Richard Prins, a director at Amphastar Pharmaceuticals (NASDAQ:AMPH), sold 7,973 shares of the company's stock for over $161,000, reducing his direct holdings by more than 21%. Despite the sale and a "Reduce" consensus rating from analysts, the company recently reported strong quarterly earnings, beating revenue and EPS estimates. Institutional investors hold a significant stake of 65.09% in Amphastar Pharmaceuticals.

Director Richard Prins sells 7,973 Amphastar (AMPH) shares at $20.30

https://www.stocktitan.net/sec-filings/AMPH/form-4-amphastar-pharmaceuticals-inc-insider-trading-activity-4d63df099eef.html
Richard K. Prins, a director at Amphastar Pharmaceuticals, Inc. (AMPH), sold 7,973 shares of the company's common stock at a price of $20.30 per share on August 11, 2026. This transaction, reported as an open market or private sale, leaves Prins with 29,625 shares of Amphastar common stock directly held. The Form 4 filing details this insider trading activity.

Amphastar CFO William Peters sells $183,886 in company stock

https://m.investing.com/news/insider-trading-news/amphastar-cfo-william-peters-sells-183886-in-company-stock-93CH-4854793?ampMode=1
Amphastar Pharmaceuticals CFO William J. Peters sold 8,180 shares of company stock for $183,886 on August 7, 2026, as part of a Rule 10b5-1 trading plan. Concurrently, he acquired 5,053 shares through employee stock option exercises for $99,998. Following these transactions, Peters beneficially owns 172,846 shares of Amphastar common stock.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement